Infergen Gives Hepatitis C Patients An Extra Chance
Approximately 50 percent of chronic hepatitis C patients do not respond to their initial course of therapy, according to Bruce R. Bacon M.D. of Saint Louis University School of Medicine.
Dr. Bacon is the lead investigator of the registration trial for Infergen, a new treatment for Hepatitis C patients that recieved FDA approval last month.
Dr. Bacon is the lead investigator of the registration trial for Infergen, a new treatment for Hepatitis C patients that recieved FDA approval last month.
posted by blog manager at
6:45 PM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home